Table 5.
Final logistic regression model regarding rheumatic disease patients enrolled at baseline
| Variables | Binary analyses | Multivariate analyses | |||
|---|---|---|---|---|---|
| No symptoms N = 4029 n (%) |
Clinical Covid-19 N = 169 n (%) |
p | OR (95% CI) | P**** | |
| Influenza vaccine within last 30 days | 1235 (30.7) | 39 (23.1) | 0.034** | 0.676 (0.465; 0.984) | 0.041 |
| IV Methylprednisolone (pulse) | 21 (0.5) | 2 (1.2) | 0.236*** | ||
| Glucocorticoids | |||||
| No | 2555 (63.9) | 97 (58.1) | 0.004** | 1 | - |
| < 10 mg/day | 1099 (27.5) | 43 (25.7) | 0.965 (0.662; 1.41) | 0.854 | |
| > = 10 mg/day | 343 (8.6) | 27 (16.2) | 2.07 (1.33; 3.22) | 0.001 | |
| scDMARDs | 1875 (46.5) | 84 (49.7) | 0.419** | ||
| Biological or tsDMARDs | 120 (3) | 7 (4.1) | 0.387** | ||
| RA | 317 (7.9) | 16 (9.5) | 0.466** | ||
| MCTD | 56 (1.4) | 2 (1.2) | > 0.99*** | ||
| SS | 39 (0.9) | 4 (2.4) | 0.042*** | 3.81 (1.31; 11.05) | 0.014 |
| SLE | 3304 (82) | 134 (79.3) | 0.414** | ||
| IM | 26 (0.6) | 1 (0.6) | 0.703*** | ||
| OA | 60 (1.5) | 1 (0.6) | 0.518*** | ||
| pSjS | 150 (3.79) | 6 (3.6) | 0.560*** | ||
| Another RD | 55 (1.4) | 4 (2.4) | 0.299*** | ||
Bold values indicate statistical significance (p < 0.05)
RA, Rheumatoid arthritis; SLE, Systemic lupus erythematous; RD, Rheumatic diseases; MCTD, Mixed connective tissue disease; SS, Systemic sclerosis; IM, Inflammatory myopathies; OA, Osteoarthritis; pSjS, Primary Sjögren syndrome; sc, synthetic conventional; ts, target-specific; DMARDs, Disease Activity-Modifying Drugs; Model 3, Outcome is COVID-19 diagnosis, according to the Brazilian Ministry of Health criteria; y, years; SD, standard deviation; med., median; min., minimum; max., maximum
*Mann–Whitney test; **Chi-square test; ***Fischer’s exact test; ****Wald test by final logistic regression model